[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339328-105":3,"doc-detail-339328-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","valrubicin-loaded-immunoliposomes-for-specific-vesicle-mediated-cell-death-in-the-treatment-of-hematological-cancers","Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers","","Valrubicin-loaded immunoliposomes (Val-ILs) were engineered using the hydrophobic antitumor prodrug valrubicin and loaded with antibodies for vesicle-mediated targeting of distinct cancer and immune cell populations. After intravenous administration in mouse models, Val-ILs rapidly localized to bone marrow and spleen and induced leukemia cell death in vivo using only limited valrubicin incorporation. Val-ILs also lowered contamination risk of CD34+ hematopoietic stem cells during autologous transplantation and showed targeting potential in immunosuppressive splenic cells in lymphoma contexts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/valrubicin-loaded-immunoliposomes-for-specific-vesicle-mediated-cell-death-in-the-treatment-of-hematological-cancers/339328/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/valrubicin-loaded-immunoliposomes-for-specific-vesicle-mediated-cell-death-in-the-treatment-of-hematological-cancers/339328.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were valrubicin-loaded immunoliposomes (Val-ILs) prepared and targeted?","Question",{"text":63,"@type":64},"Val-ILs were created by incorporating the hydrophobic prodrug valrubicin into liposomes and loading them with specific antibodies. This enabled antibody-mediated targeting after intravenous injection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What models and leukemia targets were evaluated with Val-ILs?",{"text":68,"@type":64},"Val-ILs were tested in patient-derived xenograft models generated after transplantation of pediatric B-ALL, T-ALL, or AML in immunodeficient NSG mice. Antibody-loaded Val-ILs targeted CD19, CD7, or CD33.",{"name":70,"@type":61,"acceptedAnswer":71},"What additional advantage did Val-ILs show beyond leukemia cell killing?",{"text":72,"@type":64},"Val-ILs reduced the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation, supporting clinical applicability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339328,1790196159,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nValrubicin-loaded immunoliposomes for speciﬁc vesicle  \nmediated cell death in the treatment of hematological cancers  \nAleksandra Georgievski1,2, Pierre-Simon Bellaye1,3, Benjamin Tournier 1,4, Hélène Choubley1,2,5, Jean-Paul Pais de Barros 1,2,5, Michaële Herbst6, Arnaud Béduneau2,7, Patrick Callier8, Bertrand Collin1,3, Frédérique Végran 1,2,9, Paola Ballerini 10, Carmen Garrido 1,2,9,11 and Ronan Quéré 1,2 ✉  \n© The Author(s) 2024  \n\n| | We created valrubicin-loaded immunoliposomes (Val-ILs) using the antitumor prodrug valrubicin, a hydrophobic analog of daunorubicin. Being lipophilic, valrubicin readily incorporated Val-lLs that were loaded with speciﬁc antibodies. Val-ILs injected intravenously rapidly reached the bone marrow and spleen, indicating their potential to effectively target cancer cells in these areas. Following the transplantation of human pediatric B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or acute myeloid leukemia (AML) in immunodeﬁcient NSG mice, we generated patient-derived xenograft (PDX) models, which were treated with Val-ILs loaded with antibodies to target CD19, CD7 or CD33 . Only a small amount of valrubicin incorporated into Val-ILs was needed to induce leukemia cell death in vivo, suggesting that this approach could be used toefﬁciently treat acute leukemia cells. We also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation, which is asigniﬁcant advantage for clinical applications. Using EL4 lymphoma cells on immunocompetent C57BL/6 mice, we also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen, which could be valuable in impairing cancer cell expansion, particularly in lymphoma cases. The most efﬁcient Val-ILs were found to be those loaded with CD11b or CD223 antibodies, which, respectively, target the myeloid-derived suppressor cells (MDSC) or the lymphocyte-activation gene 3 (LAG-3 or CD223) on T4 lymphocytes. This study provides a promising preclinical demonstration of the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of hematological cancers, Val-ILs have the potential to be used as a | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | precise and effective therapy based on targeted vesicle-mediated cell death. |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2024)15:328; [https://doi.org/10.1038/s41419-024-06715-5](https://doi.org/10.1038/s41419-024-06715-5) |  |\n|  |  |  |\n\nINTRODUCTION  \nAdvancements in the treatments available for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and lymphoma have led to increased complete remission rates, with 5-year survival rates exceeding 80% for ALL, 50% for AML and 70% for lymphoma [1–10] . Still, there remains a need to develop new treatment strategies aimed at reducing the intensity of therapies and enhancing patient prognosis following a relapse. Unilamellar vesicles (UVs) are vesicular structures characterized by a lipid bilayer, and their structure enables them to transport a wide range of hydrophilic and hydrophobic compounds. In particular, liposomes have been extensively employed as pharmaceutical carriers for various drugs, especially in cancer treatment [11–17] . Since their discovery over 50 years ago [18], liposomes have evolved into a promising tool in the ﬁelds of medicine, biology, and chemistry. This is a result of their biocompatibility and their  \ncapacity to encapsulate and deliver a diverse array of drugs for therapeutic purposes [11–17] .  \nDrug-loaded liposomes can be directed to tumors using passive targeting, a method that has","cbCaigzGYvKG8wZS","https://ap.wps.com/l/cbCaigzGYvKG8wZS","pdf",6577742,17,"English","# Introduction\n## Liposomes and passive targeting in hematological cancers\n# Valrubicin-loaded immunoliposomes (Val-ILs)\n## Antibody loading and vesicle-mediated targeting\n## In vivo localization and leukemia cell death","[{\"question\":\"How were valrubicin-loaded immunoliposomes (Val-ILs) prepared and targeted?\",\"answer\":\"Val-ILs were created by incorporating the hydrophobic prodrug valrubicin into liposomes and loading them with specific antibodies. This enabled antibody-mediated targeting after intravenous injection.\"},{\"question\":\"What models and leukemia targets were evaluated with Val-ILs?\",\"answer\":\"Val-ILs were tested in patient-derived xenograft models generated after transplantation of pediatric B-ALL, T-ALL, or AML in immunodeficient NSG mice. Antibody-loaded Val-ILs targeted CD19, CD7, or CD33.\"},{\"question\":\"What additional advantage did Val-ILs show beyond leukemia cell killing?\",\"answer\":\"Val-ILs reduced the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation, supporting clinical applicability.\"}]","Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers | PDF",1790029610,43,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afe1ccdf0f9fb9221e2b760ff68cbc4c.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/776df75d42aa6164f0f572237f884ff0.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06c34fc026d694d5ad6e5e8f3fc8feba.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c3cb740196adf42ab1e900123d0efac.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]